Strong Overall Revenue Growth
Q4 sales of $2.7 billion, up 7% versus prior year; full-year momentum with management exiting 2025 on a stronger rate.
Surgical & Equipment Momentum (Unity)
Surgical revenue $1.5 billion, up 6% YoY; Equipment sales $77 million, up 18% driven by Unity VCS/CS launches and strong installation demand for Unity VCS (introduced mid‑2025).
Vision Care and Contact Lens Performance
Vision Care sales $1.2 billion, up 7% YoY; Contact Lens sales $683 million, up 4% (growth driven by product innovation and price), notable share gains in reusables and daily SiHy in Q4.
Ocular Health and Truqtra Launch Success
Ocular Health sales $474 million, up 12% YoY; Truqtra surpassed ~84,000 prescriptions and achieved ~3% U.S. market share within ~5 months of launch, with >33% commercial lives covered and high refill rates—management expects it to be a meaningful 2026 growth driver.
Product Pipeline and Notable Launches
Multiple high-impact launches and pipeline items: Unity VCS award recognition and broad roll-out; PanOptix Pro strong U.S. adoption (rolling out in Japan/Australia); TruPlus (FDA PMA) launching soon; Vivity upgrade planned for 2027; Total30 Multifocal for Astigmatism launched; Valeda showing encouraging adoption and reimbursement progress (6 of 7 MACs).
Strong Cash Generation & Shareholder Returns
Generated $1.7 billion free cash flow in 2025 (vs $1.6B in 2024); free cash flow was 114% of core net income; returned $848 million to shareholders in 2025 ($682M repurchases, $166M dividends) and completed $750M repurchase program ahead of schedule.
Prudent 2026 Guidance & Margin Improvement Plan
2026 outlook: sales growth guidance 5%–7%; market assumption 3%–4%; core diluted EPS growth guidance 9%–12%; core operating margin expected to expand ~70–170 bps driven by SG&A leverage, R&D at ~9% of sales, and announced efficiency program targeting $100M annualized savings (≈$50M recognized in 2026) at an estimated $150M cost.